Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Ovarian Neoplasms 16 Lung Neoplasms 14 Endometrial Neoplasms 12 Breast Neoplasms 12 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Fallopian Tube Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 7 Neoplasm Metastasis 7 Triple Negative Breast Neoplasms 5 Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Esophageal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Stomach Neoplasms 3 Melanoma 3 Colorectal Neoplasms 3 Carcinoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Peritoneal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Brenner Tumor 2 Advanced Solid Tumour 2 Adenocarcinoma, Bronchiolo-Alveolar 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Uterine Neoplasms 1 Squamous Non-small Cell Lung Cancer 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Paclitaxel × 30 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡